Preclinical validation of fluorescence in situ hybridization assays for clinical practice

1Food and Drug Administration. Guidelines on General Principle of Process Validation. www.fda.gov/cder/guidance/pv.htm. Accessed 29 December 2004. 2College of American Pathologists Laboratory Accreditation Checklists. http://www.cap.org/apps/docs/laboratory_accreditation/checklists/checklistftp.html. Accessed 29 December 2004. 3Clinical Laboratory Improvement Amendments. CLIA:42 CFR Part 493-1253. http://www.phppo.cdc.gov/clia/regs/toc.aspx. Accessed 29 December 2004. 4New York State Health Department Clinical Laboratory Evaluation Program. http://www.wadsworth.org/labcert/clep/Survey/standardsmenu.htm. Accessed 4 January 2005. 2004, American College of Medical Genetics. Standard and Guidelines for Clinical Genetic Laboratories. 6American College of Medical Genetics. Technical and clinical assessment of fluorescence in situ hybridization: an ACMG/ASHG position statement. I. Technical considerations. Genet Med 2000; 2 6: 356–361. Schad, 1995, Building a new clinical test for fluorescence in situ hybridization, Applied Cytogenet, 21, 1 Cohen Hausmann Bilous Zarbo Dewald Dewald Dewald Dewald, 2002, Interphase FISH studies for chronic myeloid leukemia, 311 National Committee for Clinical Laboratory Standards. Fluorescence In Situ Hybridization FISH Methods for Medical Genetics: Approved Guideline. NCCLS Document MM7-A. [ISBN1-56238-524-0]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004. Montgomery, 1997, Molecular cytogenetics: definitions, clinical aspects, and protocols, 561 Dewald Ahmann Halling Thall Stupca, 2005, Using controls for molecular cytogenetic testing in clinical practice, J Assoc Genet Tech, 31, 4